Bristol Myers Squibb Pumps $200M into Princeton Biotech Expansion

PRINCETON, N.J. -- Bristol Myers Squibb, a cornerstone of New Jersey's pharmaceutical industry, broke ground Thursday on a $200 million expansion of its biotech campus here, set to create 500 jobs focused on advanced drug development. The new research facility in Princeton, Mercer County's innovation epicenter, will accelerate therapies for oncology, immunology and cardiovascular diseases, building on BMS's global headquarters presence in nearby Lawrenceville. Company executives, including site leader David Elkins, emphasized the project's role in harnessing Princeton's academic synergy with institutions like Princeton University.

The investment arrives as New Jersey solidifies its status as a life sciences powerhouse, with the state leading national AI innovations in drug discovery and biomanufacturing. Recent funding trends underscore the momentum: Princeton-based QuantX, a biotech with Shanghai ties, secured an oversubscribed $85 million Series B in early 2026 to advance oral small molecules for immunology and inflammatory diseases. BMS's expansion aligns with this surge, complementing the region's $1.7 billion in venture capital that fuels academic-biotech collaborations across pharma giants like Johnson & Johnson and Merck.

Local officials, including Mercer County Executive Brian Hughes, praised the project for injecting high-wage jobs into Princeton's economy, where median biotech salaries exceed $150,000. Construction is slated for completion by late 2027, with the facility incorporating AI-enabled labs to speed clinical trials. This follows BMS's pattern of NJ commitments, including prior Princeton investments that sustained thousands of roles amid industry shifts.